Table 1 Description of cohorts.
Stage I: Flanders-Belgian AD cohort | Stage II: Lille AD cohort | Stage II: Toronto AD cohort | Stage III: Caribbean Hispanic AD cohort | |
|---|---|---|---|---|
Total number of subjects | 1930 | 2182 | 573 | 1045 |
AD patients | 1057 | 1465 | 323 | 520 |
Mean AAO (years) (SD) | 74.9 ± 8.9 | 69.5 ± 8.2 | 75.3 ± 9.7 | 79.7 ± 8.6 |
Women (%) | 692 (65.5) | 969 (66.1) | 178 (55.1) | 369 (71.0) |
At least one APOE ε4 allele (%) | 565 (53.5) | 852 (58.2) | 182 (56.3) | 207 (39.9) |
Control individuals | 873 | 717 | 250 | 525 |
Mean AAI (years) (SD) | 65.1 ± 14.9 | 74.0 ± 8.0 | 73.0 ± 10.2 | 78.9 ± 6.5 |
Women (%) | 501 (57.4) | 447 (62.3) | 149 (60.0) | 358 (68.2) |
At least one APOE ε4 allele (%) | 235 (26.9) | 145 (20.2) | 60 (24.0) | 126 (24.0) |